The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 ...

The Texas attorney general sues major insulin makers over rising costs. Ghana confirms its first mpox case of the year. Eli Lilly's weight-loss drugs are removed from the FDA's shortage list as ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...